Obalon Therapeutics, Inc.
OBLN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,565 | $3,565 | $2,369 | $1,572 |
| - Cash | $5,707 | $4,123 | $2,515 | $693 |
| + Debt | $39 | $104 | $130 | $967 |
| Enterprise Value | -$2,104 | -$454 | -$16 | $1,846 |
| Revenue | $35 | $1,242 | $1,113 | $7,941 |
| % Growth | -97.2% | 11.6% | -86% | – |
| Gross Profit | $18 | $599 | $681 | $4,995 |
| % Margin | 52.1% | 48.2% | 61.2% | 62.9% |
| EBITDA | -$8,567 | -$2,119 | -$1,839 | -$1,841 |
| % Margin | -24,740.5% | -170.6% | -165.2% | -23.2% |
| Net Income | -$8,595 | -$2,630 | $1,474 | -$1,634 |
| % Margin | -24,822.5% | -211.8% | 132.4% | -20.6% |
| EPS Diluted | 0 | -2.25 | 18.98 | -13.22 |
| % Growth | 100% | -111.9% | 243.6% | – |
| Operating Cash Flow | $4,342 | -$4,494 | -$2,119 | $1,277 |
| Capital Expenditures | $0 | $0 | $0 | $250 |
| Free Cash Flow | $4,342 | -$4,494 | -$2,119 | $1,527 |